# Mark W Skinner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2842279/publications.pdf

Version: 2024-02-01

| 48 | 1,039 | 394421 | 454955 |
|---|---|---|---|
| papers | citations | 19 h-index | 30 g-index |

| 50 | 50 | 50 | 854 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | User-Centered Development and Testing of the Online Patient-Reported Outcomes, Burdens, and Experiences (PROBE) Survey and the myPROBE App and Integration With the Canadian Bleeding Disorder Registry: Mixed Methods Study. JMIR Human Factors, 2022, 9, e30797. | 2.0 | 2 |
| 2 | Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B. Journal of Medical Economics, 2022, 25, 386-392. | 2.1 | 0 |
| 3 | A preliminary application of a haemophilia value framework to emerging therapies in haemophilia. Haemophilia, 2022, 28, 9-18. | 2.1 | 8 |
| 4 | Nonâ€severe haemophilia: Is it benign? â€“ Insights from the PROBE study. Haemophilia, 2021, 27, 17-24. | 2.1 | 16 |
| 5 | Evidence of a disability paradox in patientâ€reported outcomes in haemophilia. Haemophilia, 2021, 27, 245-252. | 2.1 | 25 |
| 6 | Vaccination against COVIDâ€19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia, 2021, 27, 515-518. | 2.1 | 9 |
| 7 | Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488. | 2.3 | 20 |
| 8 | Evolution of haemophilia integrated care in the era of gene therapy: Treatment centreâ€™s readiness in United States and EU. Haemophilia, 2021, 27, 511-514. | 2.1 | 13 |
| 9 | The effect of emicizumab prophylaxis on longâ€term, selfâ€reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, 854-865. | 2.1 | 21 |
| 10 | Patient preferences and priorities for haemophilia gene therapy in the US: A discrete choice experiment. Haemophilia, 2021, 27, 769-782. | 2.1 | 15 |
| 11 | Evaluation of the sexual health in people living with hemophilia. Haemophilia, 2021, 27, 993-1001. | 2.1 | 2 |
| 12 | Identified unmet needs and proposed solutions in mildâ€toâ€moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts. Haemophilia, 2021, 27, 25-32. | 2.1 | 9 |
| 13 | Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal of Blood Medicine, 2021, Volume 12, 897-911. | 1.7 | 21 |
| 14 | Eliminating Panglossian thinking in development of AAV therapeutics. Molecular Therapy, 2021, 29, 3325-3327. | 8.2 | 12 |
| 15 | Achieving the unimaginable: Health equity in haemophilia. Haemophilia, 2020, 26, 17-24. | 2.1 | 54 |
| 16 | Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077. | 3.8 | 24 |
| 17 | Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?. Haemophilia, 2020, 26, 931-933. | 2.1 | 24 |
| 18 | Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia, 2020, 26, 966-974. | 2.1 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The role of telemedicine in the delivery of health care in the COVIDâ€19 pandemic. Haemophilia, 2020, 26, e230-e231. | 2.1 | 57 |
| 20 | World Federation of Hemophilia Gene Therapy Registry. Haemophilia, 2020, 26, 563-564. | 2.1 | 28 |
| 21 | The World Federation of Hemophilia Annual Global Survey 1999â€2018. Haemophilia, 2020, 26, 591-600. | 2.1 | 50 |
| 22 | Examination and Validation of a Patient-Centric Joint Metric: "Problem Joint"; Empirical Evidence from the CHESS US Dataset. Blood, 2020, 136, 25-26. | 1.4 | 2 |
| 23 | Hemophilia trials in the twentyâ€first century: Defining patient important outcomes. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 184-192. | 2.3 | 42 |
| 24 | Exploring regional variations in the crossâ€cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. Haemophilia, 2019, 25, 365-372. | 2.1 | 11 |
| 25 | The 1st <scp>WFH</scp> Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world. Haemophilia, 2019, 25, 189-194. | 2.1 | 31 |
| 26 | Testâ€retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. Haemophilia, 2019, 25, 75-83. | 2.1 | 14 |
| 27 | The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. Pilot and Feasibility Studies, 2018, 4, 58. | 1.2 | 34 |
| 28 | Core outcome set for gene therapy in haemophilia: Results of the core<scp>HEM</scp> multistakeholder project. Haemophilia, 2018, 24, e167-e172. | 2.1 | 74 |
| 29 | Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open, 2018, 8, e021900. | 1.9 | 15 |
| 30 | Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project. Haemophilia, 2018, 24, 87-94. | 2.1 | 32 |
| 31 | Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies. Haemophilia, 2017, 23, 643-644. | 2.1 | 18 |
| 32 | Assessments of outcome in haemophilia â€“ a patient perspective. Haemophilia, 2016, 22, e208-9. | 2.1 | 8 |
| 33 | NHFâ€McMaster Guideline on Care Models for Haemophilia Management. Haemophilia, 2016, 22, 6-16. | 2.1 | 50 |
| 34 | Improving comprehensive care in the haemophilia community: building on the <scp>HERO</scp> Study. Haemophilia, 2016, 22, e320-2. | 2.1 | 3 |
| 35 | Riskâ€based decision making and ethical considerations in donor compensation for plasmaâ€derived medicinal products. Transfusion, 2016, 56, 2889-2894. | 1.6 | 33 |
| 36 | Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE). Blood, 2016, 128, 5964-5964. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The national haemophilia program standards, evaluation and oversight systems in the United States of America. Blood Transfusion, 2014, 12 Suppl 3, e542-8. | 0.4 | 3 |
| 38 | Gene Therapy for Hemophilia: Addressing the Coming Challenges of Affordability and Accessibility. Molecular Therapy, 2013, 21, 1-2. | 8.2 | 23 |
| 39 | World Federation of Hemophilia: 50Âyears of advancing treatment for all. Haemophilia, 2013, 19, 475-480. | 2.1 | 9 |
| 40 | Ensuring maximum outcomes and benefits in comprehensive care for bleeding disorders through surveillance and data collection. Hematology, 2012, 17, s147-s149. | 1.5 | 2 |
| 41 | WFH: Closing the global gap â€“ achieving optimal care. Haemophilia, 2012, 18, 1-12. | 2.1 | 86 |
| 42 | Haemophilia care â€“ past, present and future from a patient perspective. Haemophilia, 2012, 18, 3-5. | 2.1 | 11 |
| 43 | Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements. British Journal of Haematology, 2011, 154, 704-714. | 2.5 | 28 |
| 44 | Cell Phones and Landlines: The Impact of Gene Therapy on the Cost and Availability of Treatment for Hemophilia. Molecular Therapy, 2011, 19, 1749-1750. | 8.2 | 16 |
| 45 | Building our global family â€“ achieving treatment for all. Haemophilia, 2010, 16, 1-10. | 2.1 | 11 |
| 46 | WFH â€“ the cornerstone of global development: 45Âyears of progress. Haemophilia, 2008, 14, 1-9. | 2.1 | 21 |
| 47 | Treatment for all: a vision for the future. Haemophilia, 2006, 12, 169-173. | 2.1 | 36 |
| 48 | The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making. Patient Preference and Adherence, 0, Volume 16, 1439-1447. | 1.8 | 12 |